Comparison of in-house HIV-1 genotypic drug resistant test with commercial HIV-1 genotypic test kit

1. Jenwitheesuk E, Watitpun C, Vibhagool A, Chantratita W. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann Clin Microbiol Antimicrob. 2003; 2:4.10.1186/1476-0711-2-4Search in Google Scholar

2. Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, et al. Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis. 2007; 60:284-9.Search in Google Scholar

3. Puthanakit T, Tangsathapornpong A, Ananworanich J, Wongsawat J, Suntrattiwong P, Wittawatmongkol O, et al. Thai national guidelines for the use of antiretroviral therapy in pediatric HIV infection in 2010. Asian Biomed. 2010; 4:505-13.10.2478/abm-2010-0065Search in Google Scholar

4. Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, Leechawengwong M, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed. 2010; 4:515-28.10.2478/abm-2010-0066Search in Google Scholar

5. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999; 353:2195-9.10.1016/S0140-6736(98)12291-2Search in Google Scholar

6. Gallant JE. Antiretroviral drug resistance and resistance testing. Top HIV Med. 2005; 13:138-42.Search in Google Scholar

7. EuroGuidelines. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. . Aids. 2001; 15:309-20.10.1097/00002030-200102160-00003Open DOISearch in Google Scholar

8. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- USA panel. Clin Infect Dis. 2008; 47:266-85.10.1086/589297Open DOISearch in Google Scholar

9. Hirsch MS, Richman DD. The role of genotypic resistance testing in selecting therapy for HIV. Jama. 2000; 284:1649-50.10.1001/jama.284.13.1649Search in Google Scholar

10. Bennett DE. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world. Curr Opin Infect Dis. 2006; 19: 607-14.10.1097/QCO.0b013e3280109ff1Open DOISearch in Google Scholar

11. Chen JH, Wong KH, Chan K, Lam HY, Lee SS, Li P, et al. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping. J Clin Virol. 2007; 39:125-31.10.1016/j.jcv.2007.03.008Open DOISearch in Google Scholar

12. Lindstrom A, Albert J. A simple and sensitive ‘in-house’ method for determining genotypic drug resistance in HIV-1. J Virol Methods. 2003; 107:45-51.10.1016/S0166-0934(02)00188-XOpen DOISearch in Google Scholar

13. Saravanan S, Vidya M, Balakrishnan P, Kumarasamy N, Solomon SS, Solomon S, et al. Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method. J Virol Methods. 2009; 159:211-6.10.1016/j.jviromet.2009.03.021292321019490976Search in Google Scholar

14. Steegen K, Demecheleer E, De Cabooter N, Nges D, Temmerman M, Ndumbe P, et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J Virol Methods. 2006; 133:137-45.10.1016/j.jviromet.2005.11.00416375980Search in Google Scholar

15. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, et al. Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods. 2010; 163:505-8.10.1016/j.jviromet.2009.11.011293296119917318Search in Google Scholar

16. Eshleman SH, Hackett J, Jr., Swanson P, Cunningham SP, Drews B, Brennan C, et al. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol. 2004; 42:2711-7.10.1128/JCM.42.6.2711-2717.200442784415184457Open DOISearch in Google Scholar

17. Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol. 2003; 41:1594-9.10.1128/JCM.41.4.1594-1599.200315385712682150Open DOISearch in Google Scholar

18. Beddows S, Galpin S, Kazmi SH, Ashraf A, Johargy A, Frater AJ, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol. 2003; 70:337-42.10.1002/jmv.1040112766994Open DOISearch in Google Scholar

19. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defic Syndr. 2001; 28:254-8.10.1097/00042560-200111010-0000811694832Search in Google Scholar

20. Jagodzinski LL, Cooley JD, Weber M, Michael NL. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol. 2003; 41:998-1003.10.1128/JCM.41.3.998-1003.200315029212624021Open DOISearch in Google Scholar

21. Mracna M, Becker-Pergola G, Dileanis J, Guay LA, Cunningham S, Jackson JB, et al. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda. J Clin Microbiol. 2001; 39:4323-7.10.1128/JCM.39.12.4323-4327.20018854311724839Open DOISearch in Google Scholar

22. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003; 51:229-40.10.1093/jac/dkg07912562686Search in Google Scholar

23. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003; 33:336-42.10.1097/00126334-200307010-0000712843744Search in Google Scholar

24. Tovanabutra S, Beyrer C, Sakkhachornphop S, Razak MH, Ramos GL, Vongchak T, et al. The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002. AIDS Res Hum Retroviruses. 2004; 20:465-75.10.1089/08892220432308770515186520Search in Google Scholar

25. Yam WC, Chen JH, Wong KH, Chan K, Cheng VC, Lam HY, et al. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J Clin Virol. 2006; 35:454-7.10.1016/j.jcv.2005.10.01216386461Open DOISearch in Google Scholar

26. Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007; 60:113-7.Search in Google Scholar

27. Myint L, Ariyoshi K, Yan H, Frater AJ, Auwanit W, Pathipvanith P, et al. Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2002; 46:3861-8.10.1128/AAC.46.12.3861-3868.200213276712435689Search in Google Scholar

28. Sugiura W, Matsuda M, Abumi H, Yamada K, Taki M, Ishikawa M, et al. Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis. 1999; 52:21-2.10.7883/yoken.52.21Search in Google Scholar

29. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17:138-45.Search in Google Scholar

30. Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM. Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 2010; 201:1303-7.10.1086/65161820350161Search in Google Scholar

31. Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009; 159:185-93.10.1016/j.jviromet.2009.03.016286314619490972Search in Google Scholar